Oxford Immunotec Reports Second Quarter 2016 Financial Results


Sign up online today & collaborate

or click here to find out more

Oxford Immunotec Reports Second Quarter 2016 Financial Results


Oxford, UK & Marlborough, USA – Oxford Immunotec Global PLC, a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced second quarter 2016 financial results.

• Second quarter revenue of $19.2 million, increased 34% compared to prior year period
• Raising revenue guidance for the full year from $79.5-$82.5 million to $82.5-$84.5 million
• Completed acquisition of Imugen, Inc. on July 1, 2016 for $22.2 million in all cash deal,
accelerating entry into tick-borne disease testing market

“We are very pleased with our financial and operating results during the second quarter,” said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. “Sales performance exceeded our expectations, with solid growth coming from the United States, China and Japan. Additionally, we are tremendously excited about the recent acquisition of Imugen, which accelerates our entry into the tickborne disease market and marks a significant advance in our goal of becoming a leader in the field of immune-regulated conditions.” For the full press release click here

CompanyOxford Immunotec Global PLC
Company Website

© Catalyst Innovation Portal 2019